GGrantIndex
← Search

Breast Cancer Program

$19,103P30FY2008CANIH

Wayne State University, Detroit MI

Investigators

Linked publications, trials & patents

Trial NCT06501040Trial NCT04479267Trial NCT04397679Trial NCT04266522Trial NCT04159896Trial NCT03875053Trial NCT03683420Trial NCT03456804Trial NCT03454529Trial NCT03453489Trial NCT03406858Trial NCT03252600Trial NCT03147885Trial NCT02824029Trial NCT02819024Trial NCT02723604Trial NCT02620865Trial NCT02568449Trial NCT02521090Trial NCT02520115Trial NCT02472275Trial NCT02470559Trial NCT02359019Trial NCT02178436Trial NCT02178163Trial NCT02173093Trial NCT02145078Trial NCT02094872Trial NCT02058706Trial NCT02037256Trial NCT01987596Trial NCT01958372Trial NCT01698658Trial NCT01504711Trial NCT01281163Trial NCT01175980Trial NCT01147016Trial NCT01116232Trial NCT01071564Trial NCT01051570Trial NCT01022138Trial NCT00984919Trial NCT00972023Trial NCT00942422Trial NCT00938626Trial NCT00935090Trial NCT00918762Trial NCT00914147Trial NCT00906503Trial NCT00903214Trial NCT00899665Trial NCT00897910Trial NCT00897741Trial NCT00897494Trial NCT00897247Trial NCT00890617Trial NCT00888654Trial NCT00769288Trial NCT00768118Trial NCT00717535Trial NCT00691015Trial NCT00559897Trial NCT00541099Trial NCT00527124Trial NCT00521261Trial NCT00520767Trial NCT00514215Trial NCT00503841Trial NCT00499694Trial NCT00482846Trial NCT00459121Trial NCT00438204Trial NCT00423826Trial NCT00410904Trial NCT00376948Trial NCT00369109Trial NCT00305747Trial NCT00303901Trial NCT00301808Trial NCT00293384Trial NCT00288028Trial NCT00258466Trial NCT00258310Trial NCT00258284Trial NCT00258245Trial NCT00258232Trial NCT00248560Trial NCT00248482Trial NCT00244946Trial NCT00244933Trial NCT00243048Trial NCT00238329Trial NCT00227721Trial NCT00217581Trial NCT00121264Trial NCT00118157Trial NCT00078923Trial NCT00068653Trial NCT00066326Trial NCT00056004

Abstract

The Breast Cancer is and comprehensive, spanning basic and translational research. Program integrated The focus of this program is the study of the mechanims involved in tumor progression and growth. Utilizing the MCF10 model of human preneoplastic, proliferative disease, members of this program are able to examine the genetic factors involved in early breast cancer development, atypical hyperplasia, carcinoma in situ and the progression to invasive cancer. Translational research employs this model as a preclinical test system for preventive agents and strategies. Basic research is also dedicated to understanding the mechanism of growth promoting cell signaling in breast cells, as well as aberations in signaling during neoplastic transformation and in resistance to hormonal and chemotherapy. These studies extend to the examination of the relationship of the structure of the estrogen receptor (ER) to its function, the influence of ER second messenger cross talk and the control of proliferation/apoptosis. In addition, new concepts involving Her-2 DNA vaccines are being explored as a means of immunological control of tumor growth. Mechanisms involved in the sensitivity/resistance of breast tumors to agents controlling growth are being examined. Joint studies with other programs are being carried out to improve dietary intervention in breast cancer prevention, examine the effect of chemopreventive agents on gene expression in preinvasive breast cancer cells and development of a serum based early detection assay for breast cancer. A better understanding of the population genetics of breast cancer in African American women is being sought as welI as further elucidation of the role of the X-chromosome in this disease. Results from basic research have led to clinical protocols to test the ameliorating effect of genistein on chemotherapy, the role of heparanase in metastasis and the development of molecular strategies for early assessment of tumor injury.

View original record on NIH RePORTER →